$PRTG new investor presentation out this week, worth a look through 🧵 1/26 
2/26 legal disclaimer
3/26 $PRTG Investment Highlights
5/26 $PRTG - Formula for Success
6/26 $PRTG #iNKT #agonists PORT-2, PORT-3, activating the innate, adaptive immune system and correcting the TMW
7/26 $PRTG PORT-2 - Rationally Designed Liposomal Formulation of IMM60 - #cytokine release
8/26 $PRTG PORT-2 Stimulates multiple arms of the immune system to produce a robust anti-cancer response
9/26 $PRTG - multiple cell types involved with anti-cancer response
10/26 $PRTG PORT-2 demonstrates superior response versus PD-1 antibody
11/26 $PRTG Interim P1 data confimed PORT-2 activity and showed good safety (#SITC2022)
12/26 $PRTG P2 evaluates front line NSCLC and refractory melanoma
13/26 $PRTG - #adenosine portfolio PORT-6 PORT-7 PORT-8 PORT-9
14/26 $PRTG - leveraging A2A and A2B alone or in combo allows for customization of treatment
15/26 $PRTG - Difference in A2A small molecules
16/26 $PRTG - fast follower with superior profile offers major competitive advantages
17/26 $PRTG - PORT-7 highly selective and potent A2B adenosine receptor antagonist
18/26 $PRTG - PORT-601 Adaptive P1a/P1b study
19/26 $PRTG - strong US and global IP positions on platforms and products
20/26 $PRTG 9 P1b/P2 data catalysts anticipated to drive value 2023/4
21/26 $PRTG summary financial data
22/26 $PRTG accelerating I/O development in untapped growth areas
23/26 $PRTG Appendix (man pretending to be busy for stock photo opportunity)
24/26 $PRTG - IMPORT-201 dose escalation with best in class design for NSCLC and #melanoma
25/26 $PRTG PORT-6 potential best in class A2A, better selectivity, potency and durability.
26/26 $PRTG - upcoming clinical development milestones
• • •
Missing some Tweet in this thread? You can try to
force a refresh
